Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial-Reference-Cited by-同舟云学术

Efficacy and safety of ravidasvir plus sofosbuvir in patients with chronic hepatitis C infection without cirrhosis or with compensated cirrhosis (STORM-C-1): interim analysis of a two-stage, open-label, multicentre, single arm, phase 2/3 trial

Published:2021-06 Issue:6 Volume:6 Page:448-458
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Andrieux-Meyer Isabelle,Tan Soek-Siam,Thanprasertsuk Sombat,Salvadori Nicolas,Menétrey Caroline,Simon François,Cressey Tim R,Said Hajjah Rosaida Hj Mohd,Hassan Muhammad Radzi Abu,Omar Haniza,Tee Hoi-Poh,Chan Wah Kheong,Kumar Suresh,Thongsawat Satawat,Thetket Kanawee,Avihingsanon Anchalee,Khemnark Suparat,Yerly Sabine,Ngo-Giang-Huong Nicole,Siva Sasikala,Swanson Alistair,Goyal Vishal,Bompart Francois,Pécoul Bernard,Murad Shahnaz

Funder

Department for International Development, UK Government

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference22 articles.

1. Progress towards hepatitis C virus elimination in high-income countries: an updated analysis;Gamkrelidze;Liver Int,2021

2. Disparity in market prices for hepatitis C virus direct-acting drugs;Andrieux-Meyer;Lancet Glob Health,2015

3. Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission;Cooke;Lancet Gastroenterol Hepatol,2019

4. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study;Blach;Lancet Gastroenterol Hepatol,2017

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug development in LMICs: could the emerging Indian model usher the southeast Asian region?;The Lancet Regional Health - Southeast Asia;2024-10

2. Design of novel broad‐spectrum antiviral nucleoside analogues using natural bases ring‐opening strategy;Drug Development Research;2024-07-20

3. Population pharmacokinetics of ravidasvir in adults with chronic hepatitis C virus infection and impact of antiretroviral treatment;Antimicrobial Agents and Chemotherapy;2024-07-09

4. ‘Unusual’ HCV genotype subtypes: origin, distribution, sensitivity to direct-acting antiviral drugs and behaviour on antiviral treatment and retreatment;Gut;2024-05-23

5. Antivirales de acción directa contra la hepatitis C: revisión narrativa;Hepatología;2024-05-02